login
  Password reminder
Cardiovascular News
Contact the editor Visit Cardiovascular News Twitter feed Visit Cardiovascular News Facebook page
 

Genous stent is a safe and effective option in STEMI patients


Friday, 09 Mar 2012 09:26
Genous
Genous

OrbusNeich has reported clinical data showing that the Genous stent is safe and effective for the treatment of patients with ST-segment elevation myocardial infarction (STEMI). Published in Revista Española de Cardiología, the data from the GENIA study show low rates of stent thrombosis and target lesion revascularisation at a mean follow-up of 538 ± 334.72 days.


In the prospective observational study, which included 139 consecutive patients undergoing primary angioplasty with implantation of one or more Genous stents, the target lesion revascularisation rate was 3.8% and the rate of definite stent thrombosis was 1.4%. In addition, the rate of cardiac death was 2.9% (four patients), and the target vessel revascularisation was 5.8%.


“STEMI is a highly prothrombotic clinical situation for which the choice of the most appropriate stent remains controversial,” said Melisa Santas-Alvarez, Departamento de Cardiología Intervencionista, Hospital Clínico de Santiago de Compostela, Spain, and first author of the study. “In high-risk situations like STEMI, drug eluting stents can delay healing of the vessel and have been associated with increased risk of thrombosis. We believe that the Genous stent’s ability to accelerate endothelialisation may reduce the risk of stent thrombosis. These results add to the growing body of knowledge confirming the safety and efficacy of Genous in STEMI patients.”


In the GENIA study, the average patient age was 64 ± 13.5 years, and 74.8% of patients were male. Notably, 20.1% of patients had multivessel disease. Patients were prescribed a regimen of antithrombotic and anticoagulant therapy in accordance with the European guidelines for the management of acute myocardial infarction.





Add New Comment

Related Items


Most popular


REVA implants first patients with Fantom scaffold
Thursday, 04 Dec 2014
REVA Medical has initiated patient enrollment with its Fantom bioresorbable drug-eluting scaffold. REVA implants first patients with Fantom scaffold

Transapical TAVI can be performed with comparable results to transfemoral TAVI in high-volume centres
Friday, 16 Jan 2015
Results from a registry of 1,000 patients undergoing transcatheter aortic valve implantation (TAVI) in a high-volume centre do not indicate a significant difference in the rates of short- and long-... Transapical TAVI can be performed with comparable results to transfemoral TAVI in high-volume centres

Too early to say that renal denervation is a failed therapy
Thursday, 04 Dec 2014
In a new consensus statement, the Joint UK Societies claim that the negative results of SYMPLICITY HTN-3 should not be used as a “rationale for abandoning” renal denervation as a “novel therapeutic ... Too early to say that renal denervation is a failed therapy

Features


ICI meeting is a “fruitful ground for new developments” in interventional cardiology
Tuesday, 13 Jan 2015
Rafael Bayer, co-chairman of the Innovation in Cardiovascular Intervention (ICI) meeting (14–16 December 2014, Tel Aviv, Israel), speaks to Cardiovascular News about the event’s unique features. ICI meeting is a “fruitful ground for new developments” in interventional cardiology

Performing TAVI in a hybrid operating room
Wednesday, 10 Dec 2014
Daniel O’ Hair believes hybrid ORs may provide distinct advantages for complex TAVI cases. He speaks to Cardiovascular News about his experience of performing TAVI in a hybrid OR. Performing TAVI in a hybrid operating room

Profiles


Sunil Rao
Thursday, 23 Oct 2014
Sunil Rao speaks to Cardiovascular News about his career highlights, including his research into ... Sunil Rao

Azeem Latib
Wednesday, 24 Sep 2014
Azeem Latib (senior interventional cardiologist, San Raffaele Hospital and EMO-GVM Centro Cuore C... Azeem Latib

Cardiac Rhythm News Vascular News Cardiovascular News Interventional News Spinal News NeuroNews
BIBA Medical BIBA MedTech Insights CX Symposium ilegx
 
Password Reminder

BIBA Medical, 526 Fulham Road, Fulham, London, SW6 5NR.
TEL: +44 (0)20 7736 8788 FAX: +44 (0)20 7736 8283 EMAIL: 
info@bibamedical.com
© BIBA Medical Ltd is a company registered in England and Wales with company number 2944429.
VAT registration number 730 6811 50.
Site Map | Terms and Conditions